Formulation of Dronedarone Hydrochloride-Loaded Proliposomes: In Vitro and In Vivo Evaluation Using Caco-2 and Rat Model

Kovvasu, S. P., Kunamaneni, P., Yeung, S., Rueda, J., & Betageri, G. V.

AAPS PharmSciTech 20.6 (2019): 226.

The objective of the present study was to develop a proliposomal formulation to increase the oral bioavailability of dronedarone hydrochloride (dronedarone HCl) by enhancing solubility, dissolution, and/or intestinal absorption. Proliposomes were prepared by using solvent evaporation method. In this process, different ratios of drug, phospholipids, such as soy phosphatidylcholine (SPC), Phospholipon 90H, hydrogenated egg phosphatidylcholine (HEPC), and dimyristoyl phosphatidylglycerol (DMPG), and cholesterol were used. Physical characterization and in vitro dissolution studies were evaluated for the prepared formulations. In vitro transport across the membrane was carried out using Caco-2 cells. Among all the formulations, the amount of drug released in dissolution was higher with DPF8 formulation (drug:DMPG Na:cholesterol:::1:2:0.2) compared to the pure drug. Also, Caco-2 cell permeability studies resulted in 2.6-fold increase in apparent permeability. Optimized formulation was evaluated in vivo in male Sprague-Dawley rats. After single oral administration of optimized formulation (DPF8), a relative bioavailability of 148.36% was achieved compared to the pure drug. Improved oral bioavailability of dronedarone could be provided by an optimized proliposomal formulation with enhanced solubility, permeability, and oral absorption.

Formulation of Dronedarone Hydrochloride-Loaded Proliposomes In Vitro and In Vivo Evaluation Using Caco-2 and Rat Model

Products Used in this Publication

Catalog NumberCASProduct NamePrice
141625-93-6141625-93-6Dronedarone HClInquiry

Related Products

Catalog NumberCASProduct NamePrice
141626-36-0141626-36-0DronedaroneInquiry
141626-57-5141626-57-5Dronedarone Hydrochloride Impurity BInquiry
141626-26-8141626-26-8Dronedarone Impurity 1Inquiry